• Home
  • |
  • Press Release
  • |
  • Global Hospital Acquired Disease Testing Market Modernization of Healthcare Infrastructure Impelling Growth

Global Hospital Acquired Disease Testing Market to Reach US$ 46.6 Billion by 2032, Propelled by Rising Consciousness Regarding Nosocomial Infections

May 16, 2019 | Healthcare

According to the latest report by IMARC Group, titled “Hospital Acquired Disease Testing Market Report by Indication (UTI (Urinary Tract Infection), SSI (Surgical Site Infection), Pneumonia, Bloodstream Infections, MRSA (Methicillin-Resistant Staphylococcus Aureus), and Others), and Region 2024-2032”, the global hospital acquired disease testing market size reached US$ 12.1 Billion in 2023. Hospital-acquired disease (HAD) tests are used to detect diseases acquired in hospitals and medical clinics, which usually appear after a surgical procedure when the protective skin layer comes into contact with possible threats and causes infection. A hospital-acquired disease testing kit is used to collect samples, test them, and determine which pathogen caused the infection. Most of the diseases generally occur among patients with compromised immunity, primarily due to sub-standard healthcare settings and negligence by hospital staff, or a prevalence of multi-drug resistant organisms (MDROs). Test instruments for hospital-acquired diseases are used by scientists to develop new drugs, culture tissues, engineer gene therapies, make vaccines, and study the toxicity of new drugs. The incubation period can range from 48 hours to 4 days following an admission to an intensive care unit (ICU) or emergency department (ER), so tests are usually conducted after the patient is discharged.

Global Hospital Acquired Disease Testing Market Trends:

The global market is majorly driven by the rising consciousness regarding nosocomial infections among the masses. This can be attributed to the rising influx of patient admissions in the hospitals. In line with this, the rising prevalence of numerous diseases and health conditions, particularly among the geriatric population, is providing an impetus to the market. Additionally, continual technological advancements in numerous testing methods, such as microarrays, polymerase chain reaction (PCR), real time location systems (RTLSs) and solid phase hybridization, are fueling the market. Moreover, favorable government initiatives for HAD testing and rising stringency in safety regulations are also impacting the market positively. Besides this, the ongoing developments in medical infrastructure due to the growing modernization in the healthcare industry are also creating a positive market outlook. The market is further propelled by considerable growth in the medical tourism industry on the global level. Apart from this, the advent of sophisticated infection detection solutions under molecular diagnostics is creating lucrative growth opportunities in the market. Some of the other factors contributing to the market include the increasing number of healthcare facilities, expanding global population, rising medical expenditure and extensive research and development (R&D) activities conducted by key players. On account of the aforementioned factors, the market is anticipated to reach a value of US$ 46.6 Billion by 2032, exhibiting a CAGR of 15.6% during 2024-2032.

Market Summary:

  • Based on the indication, the market has been segmented into UTI (Urinary Tract Infection), SSI (Surgical Site Infection), pneumonia, bloodstream infections, MRSA (Methicillin-Resistant Staphylococcus Aureus), and others. Urinary tract infection presently represents the largest segment.
  • On the geographical front, the market has been segregated into North America, Europe, Asia-Pacific, Middle East and Africa, and Latin America.
  • The competitive landscape of the market has been studied in the report with the detailed profiles of the key players. Some of these players include Abbott Laboratories, Alere, Inc., Becton, Dickinson and Company, bioMérieux SA, F. Hoffmann-La Roche Ltd., Hologic, Inc., QIAGEN, Siemens Healthcare, Diatherix Laboratories, Inc., Meridian Bioscience, Inc., Thermo Fisher Scientific, Inc. (Life Technologies Corporation), and Cepheid, Inc.

Report Scope:

Report Features Details
Base Year of the Analysis 2023
Historical Period 2018-2023
Forecast Period 2024-2032
Units US$ Billion
Segment Coverage Indication, Region
Region Covered Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Companies Covered Abbott Laboratories, Alere, Inc., Becton, Dickinson and Company, bioMérieux SA, F. Hoffmann-La Roche Ltd., Hologic, Inc., QIAGEN, Siemens Healthcare, Diatherix Laboratories, Inc., Meridian Bioscience, Inc., Thermo Fisher Scientific, Inc. (Life Technologies Corporation) and Cepheid, Inc.
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 3899
Five User License: US$ 4899
Corporate License: US$ 5899
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

30 N A
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Global Hospital Acquired Disease Testing Market to Reach US$ 46.6 Billion by 2032, Propelled by Rising Consciousness Regarding Nosocomial Infections
Purchase options

Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us

Phone: +1-631-791-1145


Phone: +91-120-433-0800


Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More